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Abstract
Background: In low-incidence countries, clinical experience of tuberculosis is becoming more limited, with
potential consequences for patient outcomes. In 2007, the Department of Health released a guidance ‘toolkit’
recommending that tuberculosis patients in England should not be solely managed by clinicians who see fewer
than 10 cases per year. This caseload threshold was established to try to improve treatment outcomes and reduce
transmission, but was not evidence based. We aimed to assess the association between clinician or hospital
caseload and treatment outcomes, as well as the relative suitability of making recommendations using each
caseload parameter.
Methods: Demographic and clinical data for tuberculosis cases in England notified to Public Health England’s
Enhanced Tuberculosis Surveillance system between 2003 and 2012 were extracted. Mean clinician and hospital
caseload over the past 3 years were calculated and treatment outcomes grouped into good/neutral and unfavourable.
Caseloads over time and their relationship with outcomes were described and analysed using random effects logistic
regression, adjusted for clustering.
Results: In a fully adjusted multivariable model (34,707 cases)there was very strong evidence that management of
tuberculosis by clinicians with fewer than 10 cases per year was associated with greater odds of an unfavourable
outcome compared to clinicians who managed greater numbers of cases (cluster-specific odds ratio, 1.14; 95 %
confidence interval, 1.05–1.25; P = 0.002). The relationship between hospital caseload and treatment outcomes was
more complex and modified by a patient’s place of birth and ethnicity. The clinician caseload association held after
adjustment for hospital caseload and when the clinician caseload threshold was reduced down to one.
Conclusions: Despite the relative ease of making recommendations at the hospital level and the greater reliability of
recorded hospital versus named clinician, our results suggest that clinician caseload thresholds are more suitable for
clinical guidance. The current recommended clinician caseload threshold is functional. Sensitivity analyses reducing the
threshold indicated that clinical experience is pertinent even at very low average caseloads, which is encouraging for
low burden settings.
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Background
In 2014, 6,520 cases of tuberculosis (TB) were notified
in England [1]. Despite a decline in such case numbers,
they are still described as ‘unacceptably high’ by Public
Health England (PHE) [1]. In other areas of health,
diseases that require specialist care but where overall
case numbers are not substantial have had their clinical
services centralised. The justification for such centralisa-
tion is based on evidence suggesting that outcomes and
survival can be improved by the treatment and manage-
ment of patients by ‘high volume’ clinical specialists and
hospitals, e.g. for various cancers [2, 3]. Along similar
lines, in 2007, the Department of Health’s TB guidance
toolkit (hereafter referred to as the ‘toolkit’) for England
advised that: “[if TB] is confirmed, the patient is best man-
aged by, or in conjunction with, a clinician (a respiratory
physician or appropriately trained infectious disease phys-
ician) who sees at least 10 confirmed cases per year” [4].
This caseload threshold was established to improve treat-
ment outcomes and thus reduce transmission, but was not
evidence based.
At the time of writing, only one publication could be
found looking at the association between clinician case-
load and TB case outcomes. Gardam et al. [5] suggested
that management by an ‘experienced’ clinician (individuals
who saw an average of one case or more a year) had a pro-
tective association on the likelihood of death among
foreign-born TB cases in Ottawa 1999–2002 (hazard ratio,
0.41; 95 % confidence interval (CI), 0.22–0.77). A second
option for recommending caseload thresholds is to do so
by treatment centre. Cegolon et al. [6] and Lake et al. [7]
examined the likelihood of treatment completion among
English and Welsh TB cases in 2001–2006 and London
TB cases in 2003–2006, respectively, given TB centre
caseload. Cegolon et al.’s [6] study, stratified by place of
birth and age, found a disadvantageous association be-
tween smaller treatment centres (caseloads of 26 and
under) and treatment completion in individuals less than
45 years old born outside the UK. Lake et al. [7] suggested
that centres with larger caseloads (130 or more cases) are
associated with a lower likelihood of treatment failure.
Using PHE notification data we sought to examine the
association between clinician and hospital caseload
and treatment outcomes, as well as discuss the relative
suitability of each method of recommending caseload
thresholds.
Methods
Study population
All TB cases notified in England to PHE’s Enhanced TB
Surveillance System (ETS) from the 1st January, 2003, to
the 31st December, 2012, with an expected treatment
duration of 12 months or less were extracted, including
their associated clinical, demographic, and laboratory
data. Rifampicin (RIF)-resistant cases, non-culture con-
firmed cases treated as multidrug resistant, and cases with
central nervous system, spinal, cryptic disseminated, or
miliary disease were excluded due to having a longer
expected duration of treatment [1]. Cases diagnosed
post-mortem were excluded as their deaths could not
have been influenced by the clinician or hospital re-
sponsible for their TB treatment.
Clinician caseload
The named medical doctor (hereafter referred to as ‘clin-
ician’) managing each case is entered at the hospital into
the ETS as free text. This field was cleaned and grouped
to assign a code for each unique clinician. Where two
clinicians were named, alternative groupings were cre-
ated, as well as a new variable to designate shared clin-
ical management (present or absent/not recorded).
Additionally, on a subset of 10 hospitals in different
parts of England (south west, south, London) that
accounted for approximately 15 % of overall cases, the
clinician name field was further checked and cleaned
by one of the authors (who had worked in these hospi-
tals) and classified according to staff type. Managing
clinician was restricted here to respiratory and infec-
tious disease specialists. This was felt to be necessary
because a review of the clinician field by this author
suggested that the named individual was sometimes a
caregiver other than the lead consultant (e.g. TB nurse or
other medical doctor). This subset of data was reserved
for the sensitivity analysis.
The toolkit provides no guidance as to the timeframe
over which a clinician’s caseload should be calculated. A
pragmatic decision was thus made to calculate mean
caseload over the preceding 3 years. This was then
grouped in the following ways: (1) above and below the
caseload threshold of 10 and (2) post hoc groupings as
described in the sensitivity analysis. If two clinicians
were named alternative caseload groups were also gener-
ated, with the default for analysis to conservatively take
the clinician with the highest caseload. Caseload was
also recalculated for the 10 hospital subset.
Hospital caseload
The hospital recorded on ETS usually represents the last
one where the patient was known to have been treated.
Hospital caseload was calculated in the same way as clin-
ician caseload. In the absence of toolkit guidance on hos-
pital caseload thresholds, mean caseload over the
preceding 3 years was grouped into four categories using
the lower quartile, median, and upper quartile.
Treatment outcomes
Case managers notify a patient’s status at 12 months to ETS;
such ‘outcomes’ were grouped into good, unfavourable, or
Stagg et al. BMC Medicine  (2016) 14:52 Page 2 of 13
neutral as per Ditah et al. [8] and Anderson et al. [9]
(Additional file 1), except where cases died within 2
weeks of being notified or or where death was consid-
ered to be too early to be influenced by the managing
clinician or hospital. Good and neutral outcomes were
pooled for the regression analysis.
Analysis
Data were managed and analysed in Stata SE version 13.
Age was categorised from a continuous variable into <20,
20–39, 40–64, and 65+ years, guided by known treatment
outcome profiles for different age groups [8, 9]. Ethnic
group was categorised into White, Black African, Black
Other (including Black Caribbean), Indian subcontinent,
and Other (e.g. Chinese), as per previous studies [9]. The
four social risk factors recorded in ETS (history of past or
current homelessness, imprisonment or drug misuse,
current alcohol abuse hindering the self-administration of
treatment) were compiled into a composite variable with
the strata: no or unknown risks, one or more previous,
one or more current; current risks override previous risks
[10]. PHE centre of notification was grouped into the
London PHE centre or elsewhere, in line with previous
evidence on the relationship between being treated in
London and treatment outcomes [9, 11, 12]. TB notifica-
tion date was categorised from a continuous variable into
pre- and post-toolkit periods (January 2006 to May 2007,
June 2007 onwards) [4]. Site of disease was combined with
smear status to generate a single variable with three strata:
solely extrapulmonary, pulmonary with or without extra-
pulmonary site(s) and smear negative or smear status
missing, and pulmonary with or without extrapulmonary
site(s) smear positive. Drug sensitivity at diagnosis was
grouped into: sensitive to all first line drugs used as stand-
ard treatment in the UK (ethambutol (EMB), isoniazid
(INH), pyrazinamide (PZA); by definition in this study all
cases were RIF sensitive), resistant to any first line drug, or
not culture confirmed. ‘Missing’ here relates to culture-
confirmed cases without any information on resistance to
EMB, INH, and PZA, as opposed to cases not linked to a
culture.
Potential confounders and effect modifiers of the rela-
tionship between clinician or hospital caseload and treat-
ment outcomes were identified as per Victora et al. [13].
For the clinician caseload modelling notification date, drug
sensitivity, previous diagnosis, social risk factors, and shared
clinical management were identified as potential effect
modifiers. Sex, age, and shared clinical management were
defined as a priori confounders, the latter due to the toolk-
it’s recommendation of its use for relatively inexperienced
clinicians. For the hospital caseload modelling, sex and age
were defined as a priori confounders and notification date,
age, being UK born (or not), ethnicity, and social risk fac-
tors as potential effect modifiers.
Descriptive analyses of the characteristics of the cohort
were undertaken. Full random effects logistic regression
was the statistical analysis method of choice to account
for clustering by clinician for the clinician caseload
models and hospital for the hospital caseload models
when calculating point estimates, standard errors (SEs)
and log likelihoods (clustering structure A). Univariate
models were built and contributed to aid the identification
of confounders for multivariable modelling. The inclusion
of variables in the final multivariable clinician and hospital
caseload models depended upon a step-by-step backwards
deletion strategy that compared the square roots of esti-
mated mean squared errors and beta coefficients between
full (all suggested confounders present) and reduced (de-
leting one suggested confounder at a time) models, whilst
simultaneously allowing for the assessment of confound-
ing and multicollinearity and the maintenance of a priori
confounders [14]. Linearity and effect modification were
assessed in these models. The estimated intra-cluster cor-
relation coefficient, ρ, was calculated per model and the
reliability of each model’s parameter estimate approxima-
tions assessed using different numbers of cut points.
Sensitivity and extended analyses
Analyses were planned to examine the sensitivity of esti-
mates to missing data using the final multivariable re-
gression models derived above. Missing outcome data
were recoded to either good/neutral or unfavourable.
Missing caseload data were either recoded to above the
threshold and placed in a single new clinician or hospital
group, or below the threshold and placed in an individ-
ual clinician or hospital group per case. Analysis using
the caseload of the alternative managing clinician, where
one was present, was undertaken. INH resistant cases
were excluded from both the hospital and clinician case-
load models in light of a recent outbreak of such cases
in London. In this outbreak, treatment regimens of 9 or
12 months were recommended, which, if patients chan-
ged regimen at the point of culture results, could have
resulted in them being recorded as still on treatment-
i.e. an unfavourable outcome- at 12 months [15]. Pa-
tients with neutral outcomes were excluded as an add-
itional sensitivity analysis for both clinician and hospital
caseload. A subgroup analysis of the 10 hospitals for
whom further cleaning of the clinician field had been
undertaken was planned.
Clustering structure A did not adjust for clustering by
hospital for the clinician caseload analysis and by clin-
ician for the hospital caseload analysis. Our data was
neither purely hierarchically structured nor were there
clean crossed-effects; clinicians frequently managed pa-
tients across various different hospitals during the time
period studied, often working in multiple hospitals
within the same year. This made adjusting for clustering
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Table 1 Univariate logistic regression of the association between clinician caseload and treatment outcome
Main exposure/potential confounders/a
priori confounders
Overall cohort Missing 12-month outcome Unfavourable 12-month outcome Univariate regressiona
No. Col. % No. Row % No. Row % OR (95 % CI)
Overall 48,838 100.0 1,468 3.0 6,777 13.9 –
Clinician caseloadb
10+ 24,092 49.3 401 1.7 3,057 12.7 P <0.001
<10 16,803 34.4 767 4.6 2,518 15.0 1.20 (1.10–1.30)
Missing 7,943 16.3 300 3.8 1,202 15.1 –
Notification date
Post-toolkit 39,264 80.4 920 2.3 5,283 13.5 P <0.001
Pre-toolkit 9,574 19.6 548 5.7 1,494 15.6 1.28 (1.19–1.38)
Missing 0 0.0 0 – 0 – –
Location
Outside London 28,212 57.8 1,338 4.7 4,069 14.4 P <0.001
Inside London 20,618 42.2 130 0.6 2,704 13.1 0.78 (0.70–0.86)
Missing 8 0.0 0 0.0 4 50.0 –
Sex
Male 26,910 55.1 829 3.1 4,051 15.1 P <0.001
Female 21,777 44.6 630 2.9 2,700 12.4 0.80 (0.76–0.85)
Missing 151 0.3 9 6.0 26 17.2 –
Age, years
<20 4,987 10.2 128 2.6 477 9.6 0.66 (0.58-0.75)
20–39 23,987 49.1 677 2.8 3,334 13.9 P <0.001
40–64 13,534 27.7 400 3.0 1,749 12.9 0.91 (0.85–0.97)
65+ 6,325 13.0 263 4.2 1,215 19.2 1.42 (1.31–1.54)
Missing 5 0.0 0 0.0 2 40.0 –
Ethnic group
White 9,313 19.1 401 4.3 1,580 17.0 P <0.001
Black African 9,666 19.8 243 2.5 1,176 12.2 0.67 (0.61–0.74)
Black other 1,473 3.0 20 1.4 213 14.5 0.85 (0.71–1.01)
Indian subcontinent 21,082 43.2 486 2.3 2,753 13.1 0.74 (0.68–0.80)
Other 5,662 11.6 131 2.3 746 13.2 0.74 (0.67–0.83)
Missing 1,642 3.4 187 11.4 309 18.8 –
UK born
No 33,946 69.5 777 2.3 4,517 13.3 P <0.001
Yes 11,946 24.5 397 3.3 1,742 14.6 1.12 (1.05–1.20)
Missing 2,946 6.0 294 10.0 518 17.6 –
Site of diseasec
Extrapulmonary only 21,681 44.4 543 2.5 2,662 12.3 P <0.001
Pulmonary smear negative/unknown 17,483 35.8 578 3.3 2,441 14.0 1.18 (1.10–1.26)
Pulmonary smear positive 9,399 19.2 313 3.3 1,623 17.3 1.53 (1.41–1.65)
Missing 275 0.6 34 12.4 51 18.5 –
Drug sensitivity
Sensitive 26,955 55.2 782 2.9 3,607 13.4 P <0.001
Resistant to INH, EMB, or PZA 1,744 3.6 53 3.0 756 43.3 5.63 (5.01–6.32)
Not linked to a culture 19,865 40.7 627 3.2 2,364 11.9 0.86 (0.80–0.91)
Missing 274 0.6 6 2.2 50 18.2 –
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complex. We tested two other clustering structures in
sensitivity analyses using multilevel mixed-effects logistic
regression with QR decomposition. Structure B assigned
all patients managed by a clinician to a single hospital,
being the one in which the greatest number of their pa-
tients were treated. When a clinician had more than one
top hospital, assignment was random between them.
This structure assumed that a clinician’s performance
was most influenced by the hospital they worked in the
most. Structure C split clinician clusters by the hospital
in which they worked. This assumed that clinicians per-
form differently in different hospitals. Analyses using
structures A and B were also run restricting to patients
with both a reported hospital and managing clinician for
the ease of comparison between methodologies.
Further sensitivity analyses were undertaken such that
hospital caseload was adjusted for in the final clinician
caseload model and vice versa, using both clustering
structures B and C.
Additional analyses to explore the impact of choosing
other clinician caseload thresholds on the post-toolkit
association with unfavourable outcomes (as such an asso-
ciation is more relevant for current policymakers) were
also planned. The first explored the impact of very low
caseloads (such as might become more common in low
burden countries) on the association with treatment out-
come, the second utilised decision tree recursive partition-
ing in JMP 12 (SW) to determine the mean caseload over
the past 3 years at which the crude association between
clinician caseload and treatment outcome was maximised.
Ethics, consent, and permissions
This study was approved by the London School of Hy-
giene MSc Research Ethics Committee (reference 7345).
Data were collected and anonymised by PHE, which has
National Information Governance Board approval to
hold and analyse national surveillance data without in-
formed consent for public health purposes under Section
251 of the National Health Service England Act 2006.
Results
TB cases
A total of 67,869 TB cases not diagnosed post-mortem,
with treatment expected to last 12 months or less, were
notified in England between 2003 and 2012 (Additional
file 2). Caseload was calculated as a mean for each year
from the preceding 3 years of data, thus cases notified
from 2003 to 2005 were utilised to assess caseload for
2006 and could not be included in the analysis. Of the
remaining 48,838 cases, 1,468 were missing a treatment
outcome, 7,943 a designated treating clinician, and 1,336
a named treating hospital. Table 1 describes the baseline
characteristics of these cases, who were generally male,
aged 20–39 years of age, had not been previously diag-
nosed with TB, and had no social risk factors. As docu-
mented in previous reports, England has a high
proportion of extrapulmonary TB cases compared to
some other low-incidence settings [1, 16]. Of all cases,
only 3.6 % were resistant to EMB, INH, or PZA (6.1 %
of those with a culture result).
Clinician caseload
Overall, 2,276 unique clinicians were present using the
main groupings and 2,351 with the alternate groupings.
Using the former, there was a median of 6 clinicians per
hospital across the entire time period (interquartile
range, 2–12) and a median caseload of 15 TB cases per
clinician over the preceding 3 years (interquartile range,
Table 1 Univariate logistic regression of the association between clinician caseload and treatment outcome (Continued)
Previous diagnosis
No 39,767 81.4 1,006 2.5 5,227 13.1 P <0.001
Yes 2,941 6.0 96 3.3 494 16.8 1.35 (1.20–1.51)
Missing 6,130 12.6 366 6.0 1,056 17.2 –
Social risk factorsd
No or unknown 47,048 96.3 1,394 3.0 6,352 13.5 P <0.001
One or more previous 829 1.7 19 2.3 144 17.4 1.42 (1.17–1.73)
One or more current 961 2.0 55 5.7 281 29.2 2.75 (2.34–3.23)
Shared clinical management
No or unknown 48,562 99.4 1,457 3.0 6,721 13.8 P = 0.02
Yes 276 0.6 11 4.0 56 20.3 1.45 (1.06–1.98)
Descriptive analysis and univariate random effects logistic regression of the association between clinician caseload and treatment outcome, England, 2006–2012.
All regression models adjusted for clustering by clinician
aOdds of an unfavourable versus a good or neutral treatment outcome; records missing an outcome excluded
bMean caseload per clinician over the preceding 3 years
cPulmonary site could be with or without extrapulmonary disease
dSocial risk factors a composite variable of homelessness, imprisonment, drug misuse and alcohol abuse; current risks override previous risks
CI Confidence interval, Col. Column, EMB Ethambutol, INH Isoniazid, OR Cluster-specific odds ratio, P, P value, PZA Pyrazinamide
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4–42). Little change in the percentage of cases being
managed by clinicians below the toolkit threshold was
seen from 2006 to 2012 (42.4 % in 2006, 38.7 % in 2012;
Fig. 1a), although calculating caseload for the previous
year only (allowing examination of caseload additionally
in 2004 and 2005) indicated a drop in the percentage be-
tween 2004 and 2006 (51.0 % in 2004, 36.8 % in 2006).
Additionally, little redistribution was seen from very low
caseloads (less than 2 or between 2 and 5) to higher ones
over time (data not shown).
Clinician caseload and TB case outcomes
Of the 48,838 cases within this cohort, 1,468 (3.0 %)
were missing outcome information, 6,777 (13.9 %) had
an unfavourable outcome, 942 (1.9 %) a neutral out-
come, and the remainder a good outcome (Table 1). Of
individuals with an unfavourable outcome, 940 (13.9 %)
had died due to the factors listed in Additional file 1,
2,229 (32.9 %) had been lost to follow-up, 3,104 (45.8 %)
were still on treatment, and 504 (7.4 %) had had their
treatment stopped. Of cases managed by clinicians
below the toolkit threshold 15.0 % had an unfavourable
outcome versus 12.7 % of cases managed by clinicians
above it; 15.6 % of cases in the pre-toolkit period had an
unfavourable outcome versus 13.5 % post-toolkit.
There was very strong evidence for clinician caseload
being associated with the odds of having an unfavourable
outcome in a univariate model; cases managed by clini-
cians below the threshold had higher cluster-specific odds
than those managed by clinicians above it (cluster-specific
odds ratio (OR), 1.20; 95 % CI, 1.10–1.30; P <0.001;
Table 1). Small amounts of within-clinician correlation
were observed with very strong evidence (ρ = 0.05; 95 %
CI, 0.04–0.07; P <0.001); the large number of cases
within some clinician groups meant it was necessary
to confirm the reliability of each model’s parameter
Fig. 1 Mean clinician and hospital tuberculosis patient caseloads over the preceding 3 years, England, 2006–2012. Percentage of tuberculosis
cases a managed by a clinician who saw fewer than 10 cases on average over the preceding 3 years, b treated by a hospital with differential
quartiles of caseload over the preceding 3 years. Dotted line year toolkit released. Error bars are 95 % confidence intervals
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estimate approximations using different numbers of
cut points. All potential confounders had evidence of
a strong association with the outcome (Table 1). Being
female, an ethnicity other than White, or notified within
London were associated with lower cluster-specific odds
of an unfavourable outcome. Being notified pre-toolkit
was associated with higher cluster-specific odds of an un-
favourable outcome (likely due to general improvements
in care over time), as was shared clinical management.
All potential confounders, aside from drug sensitivity
(which was not associated with clinician caseload in a
univariate model), were considered for inclusion in the
final model using a backwards deletion strategy. At the
end of this process, eight remained: notification date, lo-
cation, sex, age, ethnic group, having previously had TB,
social risk factors, and shared clinical management. In-
cluding age as a linear variable did not improve model
fit. There was very limited statistical evidence for effect
modification. In the final multivariable model, ρ was
similar to that of the univariate model (0.04; 95 % CI,
0.03–0.05; P <0.001) and estimate approximations were
again found to be reliable.
The multivariable model also demonstrated very strong
evidence for higher cluster-specific odds of an unfavourable
outcome being associated with management by clinicians
below the caseload threshold (cluster-specific OR, 1.14;
95 % CI, 1.05–1.25; P = 0.002; Table 2). There was weak evi-
dence for an association between treatment outcome and
shared clinical management (cluster-specific OR, 1.37; 95 %
CI, 0.97–1.94; P = 0.08).
Hospital caseload
Although the Department of Health’s toolkit suggests a
threshold at the level of the clinician, it may be more ap-
propriate to recommend one at the level of the hospital
due to the relative ease of calculation and its ability to
better capture the functionality of an entire case man-
agement team. Hospital caseload was divided into
quartiles: <27, 27–72, 73–113, >114. These figures were
conveniently similar to the thresholds proposed by Cego-
lon et al. [6] and Lake et al. [7]. When hospital caseload
was averaged over the last 3 years, little change in the pro-
portion of cases being managed below the toolkit thresh-
old was seen from 2006 to 2012 (Fig. 1b).
Hospital caseload and TB case outcomes
Overall, 15.9 % of cases treated in a hospital with less
than the lower quartile of caseload had an unfavourable
outcome versus 12.8–13.4 % in hospitals above it (Table 3).
There was very strong evidence for hospital caseload being
associated with the cluster-specific odds of having an un-
favourable outcome in a univariate model (P <0.001;
Table 4). With the upper quartile of caseload as the
baseline, only the CI of the smallest caseload strata did
not cross the null (cluster-specific OR, 1.32; 95 % CI,
1.13–1.55). In this model, there was very strong evidence
for weak within-hospital clustering (ρ = 0.03; 95 % CI,
0.02–0.04; P <0.001). All potential confounders had
Table 2 Multivariable logistic regression of the association
between clinician caseload and treatment outcome
Main exposure/confounders Multivariable regressiona
OR (95 % CI)
Clinician caseloadb
10+ P = 0.002
<10 1.14 (1.05–1.25)
Notification date
Post-toolkit P <0.001
Pre-toolkit 1.33 (1.23–1.45)
Location
Outside London P <0.001
Inside London 0.82 (0.74–0.91)
Sex
Male P <0.001
Female 0.85 (0.80–0.91)
Age, years
<20 0.72 (0.63–0.82)
20–39 P <0.001
40–64 0.88 (0.81–0.95)
65+ 1.30 (1.18–1.44)
Ethnic group
White P <0.001
Black African 0.79 (0.71–0.88)
Black other 0.88 (0.72–1.07)
Indian subcontinent 0.86 (0.79–0.94)
Other 0.86 (0.76–0.97)
Previous diagnosis
No P <0.001
Yes 1.26 (1.12–1.42)
Social risk factorsc
No or unknown P <0.001
One or more previous 1.44 (1.16–1.77)
One or more current 2.56 (2.14–3.07)
Shared management
No P = 0.08
Yes 1.37 (0.97–1.94)
Multivariable random effects logistic regression of the association between
clinician caseload and treatment outcome, England, 2006–2012. Model
adjusted for clustering by clinician and the confounders in the Table; 34,707
records in this model
aOdds of an unfavourable versus a good or neutral treatment outcome
bMean caseload per clinician over the preceding 3 years
cSocial risk factors a composite variable of homelessness, imprisonment, drug
misuse, and alcohol abuse; current risks override previous risks
CI Confidence interval, OR Cluster-specific odds ratio, P, P value
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evidence of a very strong association with the outcome
(Table 4).
Following the same process as for clinician caseload, a
final multivariable model was built for hospital caseload
that retained notification date, PHE centre of notifica-
tion, sex, age, ethnic group, UK born, and social risk fac-
tors (Table 4). Interactions were detected between ethnic
group (P = 0.004) and being UK born (P <0.001) and
hospital caseload. As ethnic group and being UK born
had 10 possible strata combinations between them, they
were condensed for the final model into: White UK
born, Other UK born, White not UK born, Black not
UK born, Indian subcontinent not UK born, Other not
UK born. The observed interaction was retained using
this categorisation (P = 0.01). Among those not born in
the UK, the likelihood of an unfavourable outcome may
increase with decreased caseload, although CIs generally
crossed the null (Table 5). In the UK born, if anything,
this pattern was reversed. The association between the
combined ethnic group and place of birth variable with
treatment outcomes is presented in Table 6; a clear pat-
tern of effect was difficult to discern. In the final model
there was very strong evidence for weak within-hospital
clustering (ρ = 0.03; 95 % CI, 0.02–0.04; P <0.001).
Sensitivity analysis
The following sensitivity analyses were undertaken: (1)
all records with missing outcome information were recoded
as having a good/neutral outcome or an unfavourable
outcome, (2) all records with missing clinician caseload
information were coded to be either above or below the
caseload threshold, (3) where present, the alternative
named clinician was used to calculate whether a case was
managed by an individual above or below the threshold.
Analysis (2) was not deemed necessary for the hospital
caseload model due to relatively low levels of missingness.
Effect estimates were relatively uniform throughout (data
not shown), which was especially reassuring given the
apparent association between hospital caseload and
treatment outcome reporting (Table 3). Exclusion of
INH resistant cases also did not appreciably alter effect
estimates, nor did the exclusion of patients with neutral
treatment outcomes (data not shown).
Encouragingly, an analysis restricted to the 10 hospi-
tals in which we undertook additional clinician name
and coding data checks to identify infectious disease or
respiratory consultants with greater certainty indicated
that the threshold caseload of 10 was still associated
with treatment outcome, albeit with low power to test
the hypothesis of no association due to the radically re-
duced size of the dataset (cluster-specific OR, 1.11; 95 %
CI, 0.84–1.46; P = 0.47; Additional file 3).
Utilising different clustering structures had little im-
pact on the results observed when point estimates and
CIs were compared like-with-like in terms of the num-
ber of included patients (Additional file 4).
In the clinician caseload model, the inclusion of hos-
pital caseload did little to alter the estimated association
between clinician caseload and treatment outcome (clus-
ter-specific OR, 1.10; 95 % CI, 1.01–1.20; P = 0.03 with
clustering structure B and cluster-specific OR, 1.10;
95 % CI, 1.01–1.21; P = 0.03 with structure C). In the
hospital caseload model, the inclusion of clinician case-
load generally reduced the point estimates observed with
both clustering structures (Additional file 5).
Different thresholds for clinician caseload
In order to explore the relationship post-toolkit between
clinician caseload and treatment outcomes at different
caseload thresholds, two versions of the final multivariable
model were run. The first reduced the caseload threshold
to one, as per Gardam et al.’s findings [5], in order to ex-
plore the impact of very low average caseloads as might be
seen in low-incidence settings. The effect estimate seen
was similar to those produced by the 10 case threshold:
(cluster-specific OR, 1.13; 95 % CI, 1.01–1.27; P = 0.04;
Additional file 6a). Recursive partitioning suggested that
the caseload threshold creating the strongest association
between clinician caseload and treatment outcome was
12.666 cases per year, which was associated with an
Table 3 Hospital caseload and treatment outcomes
Main exposure Overall cohort Missing 12-month outcome Unfavourable 12-month outcome
No. Column % No. Row % No. Row %
Overall 48,838 100.0 1,468 3.0 6,777 13.9
Hospital caseloada
114+ 12,021 24.6 126 1.0 1,564 13.0
73–113 11,662 23.9 149 1.3 1,563 13.4
27–72 11,847 24.3 297 2.5 1,520 12.8
<27 11,972 24.5 717 6.0 1,900 15.9
Missing 7,943 16.3 300 3.8 1,202 15.1
Descriptive tabulation of hospital caseload and treatment outcome, England, 2006–2012
aMean caseload per hospital over the preceding 3 years
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Table 4 Univariate and multivariable logistic regression of the association between hospital caseload and treatment outcome
Main exposure/potential confounders/a priori confounders Univariate regressiona Multivariable regressiona
OR (95 % CI) OR (95 % CI)
Hospital caseloadb
114+ P <0.001 e
73–113 1.13 (1.00–1.29)
27–72 1.06 (0.91–1.24)
<27 1.32 (1.13–1.55)
Notification date
Post-toolkit P <0.001 P <0.001
Pre-toolkit 1.25 (1.17–1.33) 1.30 (1.21–1.40)
Location
Outside London P <0.001 P = 0.16
Inside London 0.81 (0.71–0.93) 0.90 (0.77–1.04)
Sex
Male P <0.001 P <0.001
Female 0.79 (0.75–0.84) 0.85 (0.80–0.90)
Age, years
<20 0.67 (0.60–0.75) 0.70 (0.63–0.79)
20–39 P <0.001 P <0.001
40–64 0.93 (0.87–0.99) 0.92 (0.85–0.98)
65+ 1.48 (1.37–1.59) 1.44 (1.32–1.57)
Ethnic group
White P <0.001 e
Black African 0.68 (0.63–0.75)
Black other 0.88 (0.75–1.03)
Indian subcontinent 0.76 (0.71–0.82)
Other 0.74 (0.67–0.82)
UK born
No P <0.001 e
Yes 1.10 (1.03–1.17)
Site of diseasec
Extrapulmonary only P <0.001 –
Pulmonary smear negative/unknown 1.16 (1.09–1.23)
Pulmonary smear positive 1.52 (1.42–1.63)
Drug sensitivity
Sensitive P <0.001 –
Resistant to INH, EMB, or PZA 5.40 (4.86–6.00)
Not linked to a culture 0.87 (0.82–0.92)
Previous diagnosis
No P <0.001 –
Yes 1.32 (1.19–1.46)
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adjusted OR of 1.15 (95 % CI, 1.04–1.27; P = 0.01) post-
toolkit (Additional file 6b).
Discussion
In our study of the relationship between caseloads and
treatment outcomes, we observed very strong evidence
for higher cluster-specific odds of an unfavourable out-
come if TB cases were managed by clinicians who saw
less than 10 cases, on average, over the preceding 3 years
(cluster-specific OR, 1.14; 95 % CI, 1.05–1.25; P = 0.002).
Clinician caseload findings were robust when the case-
load threshold was reduced further to a mean over
3 years of one. By comparison, the picture with hospital
caseload was less clear due to a complex interaction with
ethnicity and place of birth; among those not born in
the UK, it may be unfavourable to be treated by hospi-
tals with a lower caseload, but these estimates should be
taken extremely cautiously.
This is the first study to explore whether the Department
of Health’s caseload recommendations for England are
linked to TB treatment outcomes. Within our dataset,
16.3 % of patients were missing a named clinician, but
including such patients had little impact on effect esti-
mates. The grouping of clinicians using a free-text field
may have resulted in misclassification due to spelling
errors, common surnames, clinicians moving hospitals,
etc. Additionally, some hospitals may have a policy of
recording nurses’ names, the names of non-consultants,
or assigning patients to a single clinician in ETS. The
2013–2014 Royal College of Physicians’ census identified
1,097 respiratory and 180 infectious disease and tropical
medicine consultants for England, Northern Ireland,
Scotland and Wales [17], which, even accounting for staff
turnover, suggests that we have over-estimated the num-
ber of clinicians in our dataset. Such errors are likely to be
non-differential, biasing the effect estimate towards the
null; we were also reassured to find a similar association
in a restricted dataset with additional data checks. By
comparison, the treating hospital recorded should be sub-
stantially more reliable, although only the last treating
hospital is recorded, not where the first critical weeks of
treatment are administered. Within the treatment stopped
outcome, clinical reasons, such as pregnancy, were in-
cluded; had these individuals been separable they may
have been more appropriately grouped as neutral. HIV
status and other comorbidities are unfortunately not
collected as part of TB surveillance data. TB case notifica-
tion is known to be incomplete in England [18], but it is
unlikely that missing cases are different in terms of their
relationship between caseload and treatment outcome.
Table 4 Univariate and multivariable logistic regression of the association between hospital caseload and treatment outcome
(Continued)
Social risk factorsd
No or unknown P <0.001 P <0.001
One or more previous 1.33 (1.11–1.60) 1.36 (1.12–1.66)
One or more current 2.83 (2.44–3.28) 2.67 (2.28–3.13)
Univariate and multivariable random effects logistic regression of the association between hospital caseload and treatment outcome, England, 2006–2012. All
regression models adjusted for clustering by hospital; 42,995 cases in the multivariable model, dashed variables not retained
aOdds of an unfavourable versus a good or neutral treatment outcome; records missing an outcome excluded
bMean caseload per hospital over the preceding 3 years
cPulmonary site could be with or without extrapulmonary disease
dSocial risk factors a composite variable of homelessness, imprisonment, drug misuse, and alcohol abuse; current risks override previous risks
eInteraction present between hospital caseload, ethnicity and UK born, see Table 5
CI Confidence interval, EMB Ethambutol, INH Isoniazid, OR Cluster-specific odds ratio, p P-value, PZA Pyrazinamide
Table 5 Multivariable logistic regression of the hospital caseload-treatment outcome association, stratified by country of birth/
ethnicity
Main exposure Multivariable regressiona OR (95 % CI)
UK born Not UK born
White Other White Black Indian subcontinent Other
Hospital caseloadb 114+ Baseline Baseline Baseline Baseline Baseline Baseline
73–113 1.01 (0.76–1.35) 0.95 (0.73–1.23) 1.16 (0.77–1.74) 1.00 (0.81–1.22) 1.09 (0.92–1.28) 1.14 (0.88–1.49)
27–72 0.82 (0.61–1.09) 0.68 (0.51–0.91) 1.03 (0.67–1.58) 1.02 (0.81–1.29) 0.95 (0.79–1.15) 1.31 (0.98–1.75)
<27 0.88 (0.66–1.17) 0.84 (0.61–1.15) 1.35 (0.90–2.02) 1.27 (0.99–1.63) 1.12 (0.91–1.38) 1.47 (1.10–1.96)
Multivariable random effects logistic regression of the association between hospital caseload and treatment outcome stratified by country of birth and ethnicity,
England, 2006–2012. Models adjusted for clustering by hospital and for the variables listed in Table 4
aOdds of an unfavourable versus a good or neutral treatment outcome; records missing an outcome excluded
bMean caseload per hospital over the preceding 3 years
CI, Confidence interval; OR, Cluster-specific odds ratio
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We compared a series of different clustering structures
in sensitivity analyses, each of which had their specific
limitations – structure A failed to account for clustering
by hospital within the clinician caseload analysis and
vice versa, but was the best methodology for the two
main caseload models and maximised the number of
analysable patients; structure B made strong assump-
tions about the relationship between clinicians and hos-
pitals, did not take into account the temporality of a
clinician-hospital association, and lost some of the clus-
tering effect of hospital; structure C underestimated the
impact of clinician clustering – however, the minimal
impact on the point estimates and SEs of each method
was reassuring.
Our findings on the association between clinician case-
load and treatment outcome are similar to Gardam et al.’s
Canadian study [5]. In contrast, the interaction term in
our hospital caseload model complicates the comparison
to Cegolon et al. [6] and Lake et al. [7]. The observed
association between clinician caseload and treatment
outcomes is likely more complex than a simple thresh-
old would suggest; clinicians with very large caseloads
may be under-resourced, and complex cases may be
managed by specialist clinicians who inevitably see very
few patients, e.g. paediatricians and experts on HIV-TB
co-infection or individuals with social risk factors.
Interestingly, we did not see evidence of shared clinical
management improving patient outcomes, but the naming
of two clinicians may reflect case complexity and may
also not capture all instances of dual responsibility.
Hospitals with small caseloads may have less experi-
enced clinicians, reduced availability of TB nurses, or
less access to Directly Observed Therapy (DOT) workers
(use of DOT will have been largely adjusted for in our
analysis through proxy variables such as social risk
factors, as per National Institute for Health and Care
Excellence guidance [19]). At the hospital level, the
variability of the association between caseload and
treatment outcomes by country of birth and ethnicity
may be due to diagnostic delay (and thus the severity of
disease at presentation), different sites of disease between
subgroups [1, 10], or geographical and socio-economic
factors. It should be noted that the increase in the odds of
a negative outcome associated with caseload are not as
strong as that associated with other key exposures, e.g. so-
cial risk factors.
The optimal caseload is expected to be dependent
upon the healthcare system in which clinicians and
hospitals function and how patients interact with that
system. Joined-up multidisciplinary care teams, path-
ways, and systems with good continuity and oversight
[20, 21] ensure that patients have minimal opportunities
to become poorly adherent or lost to follow-up, and in-
fluence when and how effectively clinicians can engage
with their patients. This may be particularly important
for patients with comorbidities.
If TB case numbers fell dramatically in England and
current patterns of care continued, a higher percentage
of cases will be treated by clinicians below the currently
recommended threshold, possibly driving a move to-
wards centralised models of care and increasing the need
for the national and global sharing of experience. If care
is transferred to clinicians or hospitals with larger case-
loads, however, issues may arise as expertise is lost in
certain geographical areas and patients have to travel
further for treatment [7], particularly those requiring
DOT. This may result in later and missed diagnoses and
create greater barriers to care, which could result in
poorer outcomes. Thus, our data suggesting that clinical
experience is pertinent even at a very low average clinician
caseload threshold is reassuring. It is interesting to note
that the effect estimate observed varied little between the
tested thresholds. Policymakers should consider all such
competing demands when formulating future guidance.
Table 6 Multivariable logistic regression of the birth country/ethnicity-treatment outcome association, stratified by hospital caseload
Effect modifier Multivariable regressiona OR (95 % CI)
Hospital caseloadb
114+ 73–113 27–72 <27
UK born White Baseline Baseline Baseline Baseline
Other 0.91 (0.69–1.20) 0.86 (0.67–1.09) 0.76 (0.60–0.97) 0.87 (0.68–1.12)
Not UK born White 0.91 (0.64–1.30) 1.04 (0.76–1.43) 1.15 (0.84–1.57) 1.40 (1.08–1.81)
Black 0.70 (0.55–0.90) 0.69 (0.57–0.85) 0.88 (0.73–1.07) 1.02 (0.85–1.22)
Indian subcontinent 0.77 (0.61–0.97) 0.82 (0.68–0.99) 0.89 (0.76–1.06) 0.98 (0.85–1.13)
Other 0.66 (0.50–0.87) 0.75 (0.60–0.94) 1.06 (0.85–1.34) 1.11 (0.91–1.35)
Multivariable random effects logistic regression of the association between country of birth and ethnicity and treatment outcome stratified by hospital caseload,
England, 2006–2012. Models adjusted for clustering by hospital and for the variables listed in Table 4
aOdds of an unfavourable versus a good or neutral treatment outcome; records missing an outcome excluded
bMean caseload per hospital over the preceding 3 years
CI Confidence interval, OR Cluster-specific odds ratio
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Conclusions
Although threshold recommendations at the hospital
level are likely to be easier to implement and the recording
of treating hospital is more likely to be correct than the re-
cording of a named clinician, we recommend that future
guidance is based on clinician caseload thresholds. Further
research adjusting for the different clinical and nursing
specialities involved in case management at the hospital
level and exploring such thresholds in greater detail with
more reliable clinician name data will be important to
strengthen the evidence behind our findings.
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